Comments
Lupin on Wednesday said it has received three observations from the US health regulator for its Aurangabad-based manufacturing facility. The US Food and Drug Administration (USFDA) carried out the inspection at the plant from May 6 to May 15, Lupin said in a statement. The company is confident of addressing them satisfactorily, Lupin added. Shareholders will closely monitor further development. According to reports, the unit contributes around 15 per cent to company’s US sales.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.